OncoMatch/Clinical Trials/NCT06294548

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Is NCT06294548 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Valemetostat and Atezolizumab for hepatocellular carcinoma.

Phase 1/2RecruitingUniversity of Alabama at BirminghamNCT06294548Data as of May 2026

Treatment: Valemetostat · Atezolizumab · Bevacizumab — This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Disease stage

Required: Stage III, IV, BARCELONA CLINIC LIVER CANCER (BCLC) STAGE B (NOT AMENABLE TO LIVER DIRECTED THERAPY), STAGE C (BCLC)

Locally advanced, metastatic, or unresectable disease. BCLC Stage B (not amenable to liver directed therapy) or Stage C.

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: EZH inhibitor

History of treatment with other EZH inhibitors

Lab requirements

Blood counts

Absolute neutrophil count (ANC) ≥1500/mm3; Platelet count 100,000/mm3 (no platelet transfusion within 14 days); Hemoglobin (Hgb) 9.0 g/dL (no RBC transfusion within 14 days)

Kidney function

Creatinine clearance ≥40 mL/min (measured by the Cockcroft-Gault equation)

Liver function

Total bilirubin (TBIL) ≤1.5 x ULN. ALT and AST ≤3 x ULN. Child Pugh Class A.

Cardiac function

No uncontrolled or significant cardiovascular disease, including: QTcF >470 ms, MI within 6 months, uncontrolled angina within 6 months, NYHA Class 3 or 4 CHF, inadequately controlled hypertension (SBP ≥150 mmHg and/or DBP >100 mmHg)

Child Pugh Class A. Total bilirubin (TBIL) ≤1.5 x ULN. ALT and AST ≤3 x ULN. Creatinine clearance ≥40 mL/min. ANC ≥1500/mm3; Platelet count 100,000/mm3; Hgb 9.0 g/dL. No uncontrolled or significant cardiovascular disease.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Alabama at Birmingham · Birmingham, Alabama

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify